Kangmei Pharmaceutical announced that the company plans to use its own funds to repurchase shares through centralized bidding transactions. The total repurchase capital is not less than 100 million yuan and no more than 200 million yuan, and the repurchase price is no more than 2.01 yuan/share. According to the price upper limit, it is estimated that it plans to repurchase 49.7512 million shares to 99.5025 million shares, accounting for 0.36% to 0.72% of the total share capital. The repurchase of shares will be used for employee stock ownership plans or equity incentives. If the transfer is not completed within 3 years, it will be cancelled according to law. The repurchase period is 12 months from the date of review and approval by the board of directors. As of the date the board of directors reviewed and approved the repurchase plan, the company's directors, executives, controlling shareholders and shareholders holding 5% or more of the shares had no plans to reduce their holdings for the next 3 or 6 months.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.